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abStract 
Systemic sclerosis (SSc) is characterized by autoanti-
body production, progressive microvasculopathy, and
aberrant extracellular matrix protein (ECM) synthesis
in tissues. The disease presents two major clinical hall-
marks: Raynaud’s phenomenon (RP) and skin involve-
ment, followed by varying prevalences of internal or-
gan involvement. Despite significant advances in the
management of certain organ-specific involvements
and symptoms, the research for efficient markers and
targets, to be used for an optimized treatment, is still
ongoing. Therapies targeting the vasculature (i.e. ET-1
receptor antagonists, phosphodiesterase-5 (PDE-5)
inhi bitor, angiotensin-converting enzyme inhibition,
prostacyclins), the immune system and/or the fibrotic
process (i.e. traditional disease modifying anti-rheu -
matic drugs DMARDs such as methotrexate, cyclospo -
rine or mycophenolate mofetil, biologicals like rituxi -
mab, tocilizumab or abatacept) have been or are being
eva luated in SSc. Advanced approaches, reserved to
unres ponsive SSc patients,  include autologous haema -
topoietic stem cell transplantation (HSTC) and intra-
venous immunoglobulins (IVIG). Interestingly, it is ex-
pected that new and future possible diagnostic and
therapeutical approaches in SSc will come from epige-
netic studies (MicroRNAs). 
Ideally, combination therapy in SSc seems the best
approach, together with the early intervention on the
major hallmarks of the disease in “at risk” patients, that
consists of the microvascular damage/altered function
and the autoimmune reaction, followed by the pro-
gressive and systemic fibrotic process. 
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IntroductIon
Systemic sclerosis (SSc) is a connective tissue disease
(CTD) with autoimmune reactivity, chronic vascular
and tissue stromal progressive alterations. These pro-
cesses lead to autoantibody production, progressive mi-
crovasculopathy, and aberrant extracellular matrix pro-
tein (ECM) deposition with subsequent severe organ
damage in skin, lungs, gastrointestinal tract and seve -
ral other internal organs. 
Research is still ongoing to define the initiating cause
of the pathophysiological cascade and despite signifi-
cant advances in the management of certain organ-spe-
cific involvements and symptoms, SSc remains the CTD
with the higher morbidity and mortality1,2. 
Systemic sclerosis is an orphan disease with an an-
nual incidence of 19 per million and prevalence of 19-
-75 per 100,000. The female:male ratio is 3:1, and 8:1
in mid to late childbearing years. Interestigly, juvenile
SSc (children < 16 years old) is even more rare and one
of the worst rheumatological conditions in children3. 
Based on the argument that the past SSc classifica-
tion criteria did not meet current standards for clini-
metric properties, recently, new classification criteria
based on a collaboration between the American Col-
lege of Rheumatology (ACR) and the European League
Against Rheumatism (EULAR) have been introduced4.  
The sensitivity and specificity of the classification
criteria have been significantly improved after this re-
vision, and by introducing the analysis of the micro -
vascular damage as detected by the presence of telean -
ge ctasia and capillarscopic features. 
Additionally, to overcome the issue of properly clas-
sifying subjects with subclinical disease, Very Early Di -
sease Onset Systemic Sclerosis (VEDOSS) criteria have
been proposed5. 
SyStemIc ScleroSIS hallmarkS
Systemic sclerosis is clinically characterised by two ma-
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jor hallmarks: Raynaud’s phenomenon (RP) and skin
involvement, followed by varying prevalences of in-
ternal organ involvement.
Based on the extension on skin involvement pa-
tients with SSc can be classified into limited cutaneous
(lcSSc)  or diffuse cutaneous (dcSSc) involvement. Pa-
tients with dcSSc with severe organ involvement may
have the worst prognosis.
The vast majority of patients with SSc have RP (bi
or tri-phasic colour changes of extremities upon ex-
posure to cold or stress)6. It is noteworthy that the RP
may occur in a healthy population (without any asso-
ciation with CTD) or in secondary Raynaud's phe-
nomenon (SRP) (mostly due SSc). The key point as a
clinical medical doctor or specialist is to be able to
make this differential diagnosis. The combination of
capillaroscopy and serology allows to do so. 
Moreover, this combination also allows to pinpoint
those patients who only have RP at baseline, without
any sign of another CTD, who will progress to a secon -
dary over long time follow up (13.6% of patients with
isolated RP at baseline)7.
Next to RP and skin involvement, other clinical
complications are frequent in SSc.
Digital ulcers (DU) and gastrointestinal involvement
occur frequently.  DU occur in  a major part of SSc pa-
tients in their disease course. They are associa ted with
an important morbidity (pain, reduced qua lity of life,
disability and disfigurement) and may evolve into tis-
sue necrosis and amputation8. 
Gastrointestinal involvement is frequent in sclero-
derma (almost 90%) and in 10% of cases is the pre-
senting feature of the disease9. Of note, several patients
are asymptomatic, ranging from 20% for small bowel
to half for esophageal involvement. Most frequent gas-
trointestinal organs affected in SSc are the oesophagus,
followed by the anorectum and the small bowel, whe -
reas severe gastrointestinal involvement luckily affects
only 8% of the patients, but is associated with a high
mortality, with a 9 year survival of only 15%. Also, the
risk of malnutrition is high in SSc, with over 28% of
patients being at medium or high risk of malnutrition.
Other complications are less frequent but linked
with high mortality in SSc and should therefore be
screened for. Among those pulmonary arterial hyper-
tension (PAH), severe lung fibrosis, myocardial in-
volvement and scleroderma renal crisis are associated
with high mortality10. 
Screening for these afflictions is recommended. In
this way screening for PAH is standardly incorporated
into daily SSc management and screening according
to highly performant the DETECT algorythm which
encompasses echocardiography, pulmonary functio -
nal tests and optionally BNP or NT-proBNP. 
Even though, at present, no therapies have attested
to be able to stop the natural progression of the disease,
still there are organ specific effective treatments. 
Both for PAH and digital trophic lesions therapies have
attested treatment effect through randomised con-
trolled trials. 
Therapies targeting the vasculature (i.e. ET-1 re-
ceptor antagonists, phosphodiester-ase-5 (PDE-5)
inhi bitor, ACE inhibition, prostacyclins), the immune
system and/or the fibrotic process (i.e. traditional
DMARDs such as methotrexate, cyclosporine or my-
cophenolate mofetil, biologicals like rituximab or
tocilizumab and abatacept) have been or are being
evaluated in SSc.
Rather than waiting for the clinical overt disease to
set in, eyes are geared to diagnose the disease “early”
or “very early”, with the aim to futurely be able to treat
selected SSc patients before the clinical complications
occur.
early markerS of SyStemIc ScleroSIS 
Key pathways and mediators involved in the SSc
pathophysiology can be identified within the skin and
blood vessels, and several new molecules are now 
being examined in early stage clinical trials. 
However, early clinical symptoms (i.e. RP) and
biomarkers (i.e. serum autoantobodies) seem to repre -
sent the best “early signals” of possible SSc to be con-
sidered.
Among them, RP may be present in 5% of healthy
subjects, with a higher prevalence for females, where-
as appro ximately 90% of SSc patients and 85% of
mixed connective tissue disease (MCTD) patients, pre-
sent RP as an early symptom. 
As matter of fact, the best system for the early diffe ren -
tial diagnosis between primary and secondary RP (PRP,
SRP) and prediction of organ involvement in SSc is con-
sidered the nailfold videocapillaroscopy (NVC)11-14. Of
course, the presence of defined and validated criteria for
the definition of NVC SSc pattern should be considered
in order to better distiguish specific from non-specific
microvascular abnormatities.
Therefore, several authors stated that NVC abnor-
malities could be observed in healthy individuals as
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well as in primary RP (PRP) subjects15,16. 
Indeed, NVC abnormalities in a subject with isola -
ted RP are known to predict for evolution to a CTD
within 2 years17. A prospective study on 3029 consecu -
tive patients with RP, showed predictivity of sclero-
derma type capillary changes during follow-up of pa-
tients transitioned to scleroderma spectrum diseases18. 
A further prospective study on 412 patients fol-
lowed up for 5 years, individuated the percentage of
patients initially diagnosed with PRP and later transi-
tioned to SRP associated to SSc19. The study offereded
a hint at the increased probability of transition in RP
patients into SRP presenting at baseline observation
with capillary dilations and slight reduction of capil-
lary number compared to those which did not present
such alterations19.
In a more recent study, a significant increased base-
line frequency of average, arterial and venous capillary
dilations, was found in SRP patients, and a threshold
value with high negative predictive value for reassu -
rance of patients that probably are not going to deve -
lop SSc20. Indeed, the very early diameter threshold
value (over 30 μm) here observed, might represent the
structural alteration preceding the uniform capillary
loop dilation, that underlies the formation of the giant
capillaries (over 50 μm), pathognomonic for the “Ear-
ly” SSc pattern21.
Together with the specific NVC alterations, speci fic
autoantibodies (ANA, ACA and TOPO-I) seem to play
an important role in the pathophysiology of SSc and in
SRP patient they seem to represent another reliable ear-
ly biomarker to monitor the evolution towards SSc21.
More specifically, the combined presence of SSc-speci -
fic NVC patterns together with the presence of SSc-
-spe cific autoantibodies (anti-centromere, anti-topoi-
somerase I as well as anti-Th/To and anti-RNA polyme -
rase III), in a patient group with isolated RP and no
other sign of CTD, has a positive predictive value of
79% to predict which patients will develop SSc over ti -
me22. This study, as first, prospectively attested that the
com bination of a SSc pattern on capillaroscopy, in
com bination with an SSc-specific antibody, is highly
pre di cti ve of a patient prone to develop SSc. On the
other hand, the combination of a normal capillaros co -
py together with the absence of one of the SSc-speci -
fic antibodies has a negative predictive value of 93%.
More recently, non-specific antibodies against the
angiotensin receptor type-1 (AT1R) together with anti-
-en dothelin-1 (ET) receptor type-1 (ETAR) autoan -
tibo dies have been studied in patients with SSc and
about 85% of patients fulfilling the former ACR crite-
ria showed autoantibodies against AT1R and ETAR23,24. 
The antibodies are agonistic for endothelin-1 (ET1)
and therefore exhibit functional properties, which may
contribute to SSc pathogenesis25,26. Both antibody le -
vels seem to correlate with each other suggesting a
strong interrelationship, which is possible since both
the angiotensin as well as the endothelin system me-
diate similar effects23. 
In addition, high levels of anti-AT1R/ETAR anti-
bodies were found to be associated with vascular and
fibrotic SSc complications23. In particular, a recent stu -
dy showed their capacity to predict the development
of PAH and of PAH-related mortality and, as conse-
quence, failure of response to PAH therapy26. Anti-
-AT1R antibodies below 15.8 units and anti-ETAR an-
tibodies below 18.3 units revealed a negative predicti -
ve value of 76.9% and 77.1%, respectively.
targeted therapIeS In SyStemIc 
ScleroSIS
Therefore, the early detection of microvascular da mage
(NVC pattern) together with RP and autoimmune
biomarkers (autoantibodies) might be used to stratify
patients for the risk of SSc development and subse-
quently start early-targeted therapies27,28.
For example, combination treatment with im-
munosuppressive and vasoactive drugs, should repre-
sent an important early intervention with possible di -
sease modifying activity29,30. Key question here is when
to start early intervention. In order to be able to reply
to this question indices are needed that evaluate which
patients with early (scleroderma pattern and SSc-speci -
fic antibody) or very early (VEDOSS criteria) will de-
velop a severe disease course5.
Additionally, the concept of targeted therapy for SSc
include at least two different approaches31. One 
approach to targeted therapy in SSc is the possible ear-
ly treatment of individual disease mechanisms such as
immune activation/inflammation, vascular disease or
fibrosis. The other classical approach is to targeting
specific organ based complications in overt disease,
such pulmonary arterial hypertension, or specific
symptoms such as RP, gastrooesophageal reflux or scle-
roderma renal crisis. 
Interestinlgly, final result of the local SSc immune-
inflammatory process is the activation of a sort of ne -
ver ending “wound healing” mechanism (tissue repair),
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that is finally characterized by the recruitment of cir-
culating fibrocytes, resident fibroblasts and their pre-
cursors (pericytes) and activation into myofibroblasts,
with high production of extra ECM proteins32,33. 
Furthermore, microvascular alterations and re-
duced capillary density, reduce blood flow, impair tis-
sue oxygenation and the generated tissue hypoxia, fur-
ther enhances the production of ECM proteins by SSc
fibroblasts34,35.
In relation to the “tissue repair”, the endothelial-to-
mesenchymal cell transition (EndoMT) process has
been recently recognized a strongly implicated process
and a potentially target for the early diseases modi fying
intervention in SSc36. 
In fact, the endothelial/microvascular injury and the
myofibroblast activation, are crucial events that seem
to contribute to the development of fibrosis in CTD
such as SSc, and it seems mainly related to the local in-
creased production and influence of several growth
factor molecules including TGF-β and ET-133,37. 
Interestingly, several fibrotizing conditions seem to
involve the EndoMT process together with high ET-1
local concentrations, such as the cardiac fibrosis in dia -
betic hearts, the idiopathic pulmonary fibrosis or the
scleroderma renal crisis in both glomeruli and arterio-
lar lesions38-40. 
Treatments targeting in SSc potential mediators of fi-
brosis and potential pathways (TGF-β, ET-1, VEGF,
PDGF, FGF) have been tested or are under evaluation
in clinical trials, with different results (Table I).
Very recently a further clinical trial has been des -
cribed that blocks TGFbeta more effectively then ear-
lier temptatives, and although this was an open label
study, it does suggest that the skin score may be im-
table I. poSSIble targeted therapeutIc approacheS In SyStemIc ScleroSIS (IncludIng agentS
under evaluatIon)
Immune-inflammatory target Agent to the target
CD-20 Rituximab








αMSH, IL-10, CCL2 AIMSPRO (HCS)  
LPA1 ACT12339    
Ig Immunoglobulin IV  
Vascular target Agent to the target
ETA/ETB receptor Bosentan, Macitentan 
ETA receptor Ambrisentan, Zibotentan 
cGMP agonist Riociguat 
IP receptor agonist Selexipag 
Pro-fibrotic molecule target Agent to the target
c-Abl, c-Kit, PDGF Imatinib, Dasatinib, Nilotinib  
VEGF - PDGF - FGF Nintedanib
TGFβ Anti-αvβ6 integrin    
TGFβ1 CAT-192, P144  
TGFβ1, β2, β3 GC-1008
CCN2 FG-3019
TNF-α - L-1β - TGF-β Pirfenidone
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proved and that gene expression signatures may be
atte nuated with this approach41. The durability and
clinical meaning of this therapeutic strategy remains to
be determined in future studies, but this recently
publi shed clinical trial provides strong support to the
rationale for targeting TGF-β in SSc, especially for skin
disease42.
In this perspective of targeted therapy in SSc, two
very recent clinical studies have shown that long-term
treatment with ET-1 receptor antagonist modifies the
progression and morphology of the nailfold microvas-
cular damage, as assessed by NVC, in patients with
SSc, and respectively affected by pulmonary arterial
hypertension and DU (in combination with iloprost),
over a 1-3 year follow-up period43,44. 
Interestingly, both studies showed, at the nailfold
capillaroscopy, at least after 1 year, a significant in-
creased number of capillaries with reduced avasculari -
ty and increased neoangiogenesis, suggesting the pos-
sible achievement of a miscrovascular/tissue de-re-
modelling in SSc. The effects might be related to in-
terferences exerted by ET-1 receptor antagonists on the
already mentioned process of EndoMT and on the
TGF-β activities in SSc45-47.
An efficient system to target the autoantibody pro-
ducing B cells in SSc is emerging from the successfull
use of rituximab (RTX) in treatment of SSc patients48.
As matter of fact, a recent clinical open-study by de-
pleting B cells with RTX on a 2-treatment course
(months 0/6), was found to be well tolerated and to
have potential efficacy for skin disease and stabilization
of internal organ status in early dcSSc49. Moreover, sta-
bilisation of microcirculation (number of capillaries)
has also been attested by this regimen50.
In a more recent study, the comparison of RTX trea-
ted SSc patients versus untreated matched-controls
showed improvement of skin fibrosis and prevention
of worsening lung fibrosis, and further supports the
therapeutic concept of B cell depletion in order to re-
duce autoantibody production/effects in SSc pa-
tients51,52.
advanced and future therapIeS 
for SyStemIc ScleroSIS
A possible therapeutic option to be considered in SSc
patients who are refractory to conventional treatments
is the autologous haematopoietic stem cell transplan-
tation (HSTC)53. 
The mechanisms responsible for  the benefits of
HSTC are not already fully understood, and possibly
it induces a re-establishment of immunological tole -
rance together with non-specific  immunosuppressive
activities.  However, HSTC seems to cause an impro -
ve ment of vasculopahy, modified Rodnan skin thick-
ness score (MRSS) and lung function, in patients with
dcSSc and mild-moderate internal organ involvement
(maximum disease duration of 4–5 years) or dcSSc pa-
tients with progressive internal organ involvement54. 
However, despite the potential benefits, HSTC is,
dangerous therapeutic option with a high risk of death
and a higher morbidity rate and new trials try to opti-
mize this approach especially in dcSSc55. 
A further therapeutic option in SSc patients resistant
to conventional therapies, seems be represented by in-
travenous immunoglobulins (IVIG), but their mecha-
nisms of action remain unclear56. Recent clinical data
about the effects of IVIG on SSc patients report that
this approach may  improve  several clinical manifesta-
tions such as skin, joint and lung involvement al-
though optimal dosages and timing of administration
are not yet defined. A double- blind, randomised, pla -
cebo-controlled study is in progress to assess the safe-
ty and  efficacy  of IVIG  in  scleroderma  patients57. 
Interestingly, new and future possible diagnostic
and therapeutical approaches in SSc will come from
epigenetic studies58. 
In fact, the interest about microRNAs (miRNAs) that
are non-coding RNAs regulating a large variety of bio-
logical functions in plants and animals, is growing59.
Each miRNA expressed in a cell may target about 100
to 200 messenger RNAs that it downregulates. It 
appears that about 60% of human protein coding ge-
nes are regulated by miRNAs, whilst many miRNAs
are epigenetically regulated. 
There is currently good evidence for the role of 
miR NAs in fibrotic diseases, either organ-specific or
sys temic fibrosis, such as in SSc60. Whereas the exact
targets of these miRNAs are unknown, for some of them
it is know,  since they are regulating key downstream
pathways in pathogenesis of diseases such as miRNA-
-29, which is a key mediator of fibrosis61. Gene therapy
with the restoration of miRNA-29, at least in an animal
model of fibrosis, appears to reduce fibrosis62.
Therefore, pharma companies are searching for
miRNA technologies for modulating various fibrotic
conditions and recent  data are emerging on the role of
increasing miRNAs in vivo, especially miRNA-29a, to
restore its function and thus suppress fibrosis without
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the need for viral vectors63.
As matter of fact, in complex diseases such as SSc,
it may be that the clinical course of the disease is in-
fluenced by the expression of miRNAs, which them-
selves are epigenetically altered by body environmenal
factors (i.e. estrogens).
concluSIonS
The fast and progressive increase in knowledge about
the mechanisms underlying the  SSc pathogenesis
should offer new possible targets for therapeutical 
approaches adressed to an efficient and early disease-
modifying strategy (Table I). 
Combination therapy in SSc seems the best 
approach, as well as the early intervention on the major
hallmarks of the disease in “at risk” patients that con-
sists of the microvascular damage/altered function and
the autoimmune reaction, followed by the progressi-
ve and systemic fibrotic process. 
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